We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BellBrook Labs Granted Patent for Transcreener Assay Technology
News

BellBrook Labs Granted Patent for Transcreener Assay Technology

BellBrook Labs Granted Patent for Transcreener Assay Technology
News

BellBrook Labs Granted Patent for Transcreener Assay Technology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BellBrook Labs Granted Patent for Transcreener Assay Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BellBrook Labs, a leading provider of high throughput screening tools for the drug discovery industry, today announced that the U.S. Patent and Trademark Office issued a patent to BellBrook Labs the Transcreener™ HTS Assay platform.

Our proprietary Transcreener™ HTS Platform was developed to move more new targets into HTS more rapidly, and to streamline selectivity profiling within a target family. It relies on homogenous fluorescent immunodetection of nucleotides, including ADP, UDP, AMP and GMP, which are formed by thousands of cellular enzymes. Among these are group transferase families, such as kinases, ATPases and glycosyltransferases, that catalyze the covalent regulatory reactions that are central to cell signaling. Each Transcreener™ Assay provides a generic detection method for multiple enzyme families. This means that you can focus on evaluating new therapeutic strategies and optimizing lead molecules rather than on time-consuming assay development for individual targets. The Transcreener™ platform is unique in this regard; there is no other HTS platform with the potential to eliminate so much costly assay development for so many drug targets. Since introduction of the first Transcreener assays, the platform has been rapidly validated and adopted by pharmaceutical and biotechnology screening labs around the world.

Advertisement